Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Aldose reductase inhibitor in phase III at Fujisawa

Oct. 11, 1996

Antidiabetic agents from Yamanouchi's clinical pipeline

Oct. 11, 1996

New approval for Lilly's Humalog

Oct. 11, 1996

UCSF scientists discover protein involved in insulin resistance

Oct. 11, 1996

Novel, highly potent antihyperglycemic agents from SmithKline Beecham

Oct. 11, 1996

Nissan Chem. claims hypoglycemic agents for diabetes

Oct. 11, 1996

Progress in development of NPS's R-568

Oct. 11, 1996

Future metabolic agents in the Yamanouchi pipeline

Oct. 11, 1996

ProScript and Roche to develop compounds for cachexia

Oct. 11, 1996

Appetite-suppressing effects of urocortin

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.